Page 3 - Colleen Loo News Today

Australia is set to become the first country to legalize clinical prescribing of MDMA and psilocybin, the main psychoactive ingredient in magic mushrooms, for certain mental health disorders.

Magnet therapy for treatment-resistant depression is expensive in the private sector, but subsidised by Medicare.

On 3 February 2023, the Therapeutic Goods Administration (TGA) made a surprising announcement. From 1 July, authorised psychiatrists will be able to prescribe MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatmen

Australians suffering from treatment-resistant mental health problems will soon have access to psychedelic therapies including MDMA and psilocybin,...

"It is a bit of a wild west at the moment."

AUCKLAND, New Zealand, Jan. 26, 2023 /PRNewswire/ -- Douglas Pharmaceuticals, a New Zealand Pharmaceutical company focused on specialty generic and repurposed drug development, today announced

Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107

Five different antidepressants didn’t help relieve Elissa, but she is among the first people in Australia to receive a new drug for treatment-resistant depression.

Five different antidepressants didn’t help relieve Elissa, but she is among the first people in Australia to receive a new drug for treatment-resistant depression.

Five different antidepressants didn’t help relieve Elissa, but she is among the first people in Australia to receive a new drug for treatment-resistant depression.